Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy - Germany
doi 10.1007/s00262-019-02352-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pembrolizumab-Induced Sarcoid-Like Reactions During Treatment of Metastatic Melanoma

Radiology
Nuclear MedicineRadiologyImaging
2018English

Nanoparticles for Uveal Melanoma Treatment

2008English

Cutaneous CD56 + T-Cell Lymphoma Developing During Pembrolizumab Treatment for Metastatic Melanoma

JAAD Case Reports
Dermatology
2018English

Nestin Expression in Primary and Metastatic Uveal Melanoma - Possible Biomarker for High-Risk Uveal Melanoma

Acta Ophthalmologica
MedicineOphthalmology
2018English

Pcn34 - Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-Squamous NSCLC – A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Verification of EZH2 as a Druggable Target in Metastatic Uveal Melanoma

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2020English

Cost Effectiveness of PD-L1-Based Test-And-Treat Strategy With Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

PharmacoEconomics - Open
Health PolicyPharmacology
2019English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Immunotherapy
OncologyAllergyImmunology
2019English

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy